CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION)
This study is ongoing, but not recruiting participants.
Sponsor:
CardioMEMS
Information provided by (Responsible Party):
CardioMEMS
ClinicalTrials.gov Identifier:
NCT00531661
First received: September 18, 2007
Last updated: February 28, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: November 16, 2012
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Single Blind (Subject); Primary Purpose: Treatment |
| Condition: |
Heart Failure, Congestive |
| Intervention: |
Device: HF Pressure Measurement System |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| No text entered. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| No text entered. |
Reporting Groups
| Description | |
|---|---|
| Treatment | TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System |
| Control | CONTROL group: standard of care HF management |
Participant Flow for 2 periods
Period 1: 6 Months
| Treatment | Control | |
|---|---|---|
| STARTED | 270 | 280 |
| COMPLETED | 244 | 254 |
| NOT COMPLETED | 26 | 26 |
Period 2: Study Duration: 15 Months Avg. Follow-up
| Treatment | Control | |
|---|---|---|
| STARTED | 244 | 254 |
| COMPLETED | 186 | 197 |
| NOT COMPLETED | 58 | 57 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| Treatment | TREATMENT group: standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System |
| Control | CONTROL group: standard of care HF management |
| Total | Total of all reporting groups |
Baseline Measures
| Treatment | Control | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
270 | 280 | 550 |
|
Age
[units: participants] |
|||
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 150 | 155 | 305 |
| >=65 years | 120 | 125 | 245 |
|
Age
[units: years] Mean ± Standard Deviation |
61.3 ± 13.0 | 61.8 ± 12.7 | 61.6 ± 12.8 |
|
Gender
[units: participants] |
|||
| Female | 76 | 75 | 151 |
| Male | 194 | 205 | 399 |
|
Region of Enrollment
[units: participants] |
|||
| United States | 270 | 280 | 550 |
Outcome Measures
| 1. Primary: | Rate of Heart Failure Related (HFR) Hospitalizations [ Time Frame: 6 months ] |
| 2. Primary: | Freedom From a Device/System-related Complication (DSRC). [ Time Frame: 6 months ] |
| 3. Primary: | Freedom From Pressure Sensor Failure [ Time Frame: 6 months ] |
| 4. Secondary: | Change From Baseline in Pulmonary Artery Mean Pressure [ Time Frame: 6 months ] |
| 5. Secondary: | Proportion of Patients Hospitalized for Heart Failure [ Time Frame: 6 months ] |
| 6. Secondary: | Days Alive Outside of the Hospital [ Time Frame: 6 months ] |
| 7. Secondary: | Quality of Life - Minnesota Living With Heart Failure Questionnaire (MLHFQ) [ Time Frame: 6 months ] |
| 8. Other Pre-specified: | Rate of HFR Hospitalizations [ Time Frame: Study duration: average patient follow-up of 15 months ] |
| 9. Other Pre-specified: | Freedom From a Device/System-related Complication (DSRC) [ Time Frame: Study duration: average patient follow-up of 15 months ] |
| 10. Other Pre-specified: | Freedom From Pressure Sensor Failure [ Time Frame: Study duration: average patient follow-up of 15 months ] |
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
No publications provided
| Principal Investigators are NOT employed by the organization sponsoring the study. |
| There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: Jordan Bauman
Organization: CardioMEMS, Inc.
phone: 4043458235
e-mail: jbauman@cardiomems.com
Organization: CardioMEMS, Inc.
phone: 4043458235
e-mail: jbauman@cardiomems.com
No publications provided
| Responsible Party: | CardioMEMS |
| ClinicalTrials.gov Identifier: | NCT00531661 History of Changes |
| Other Study ID Numbers: | CM-06-04 |
| Study First Received: | September 18, 2007 |
| Results First Received: | November 16, 2012 |
| Last Updated: | February 28, 2013 |
| Health Authority: | United States: Food and Drug Administration |